Cellular uptake of 3H-bestatin in tissues of mice after its intravenous injection

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 798-804

  Scornik, Oscar A ^a   Botbol, Violeta ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; BIOLOGICAL MARKER; DRUG DERIVATIVE; LEUCINE; PROTEINASE INHIBITOR; SUCROSE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; ERYTHROCYTE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; EXTRACELLULAR SPACE; INTESTINE; KIDNEY; LIVER; MALE; METABOLISM; SKELETAL MUSCLE; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL MARKERS; ERYTHROCYTES; EXTRACELLULAR SPACE; INJECTIONS, INTRAVENOUS; INTESTINES; KIDNEY; LEUCINE; LIVER; MALE; MICE; MUSCLE, SKELETAL; PROTEASE INHIBITORS; SUCROSE; TISSUE DISTRIBUTION;

EID: 0030610839     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. H. Umezawa, M. Ishizuka, T. Aoyagi, and T. Takeuchi: Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J. Antibiot. 29, 97-99 (1976).
2. H. Umezawa (ed.): "Small Molecular Immunomodifiers of Microbial Origin," pp. 1-254. Pergamon Press, New York, 1980.
3. F. Abe, G. Alvord, M. Koyama, A. Matsuda, and J. E. Talmadge: Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. Cancer Immunol. Immunother. 28, 29-33 (1989).
4. T. Takeuchi: Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. J. Cancer Res. Clin. Oncol. 121, 505-510 (1995).
5. V. Botbol and O. A. Scornik: Degradation of abnormal proteins in intact mouse reticulocytes: accumulation of intermediates in the presence of bestatin. Proc. Natl. Acad. Sci. U.S.A. 76, 710-713 (1979).
6. V. Botbol and O. A. Scornik: Intermediates in the degradation of abnormal globin. Bestatin permits the accumulation of the same peptides in cell-free extracts as in intact reticulocytes. J. Biol. Chem. 254, 11254-11257 (1979).
7. V. Botbol and O. A. Scornik: Peptide intermediates in the degradation of cellular proteins. Bestatin permits their accumulation in mouse liver in vivo. J. Biol. Chem. 258, 1942-1949 (1983).
8. V. Botbol and O. A. Scornik: Role of bestatin-sensitive exopeptidases in the intracellular degradation of hepatic proteins. J. Biol. Chem. 264, 13504-13509 (1989).
9. V. Botbol and O. A. Scornik: Measurement of instant rates of protein degradation in the livers of intact mice by the accumulation of bestatin-induced peptides. J. Biol. Chem. 266, 2151-2157 (1991).
10. V. Botbol and O. A. Scornik: Measurement of instant rates of protein degradation in skeletal muscle of intact mice by the accumulation of bestatin-induced peptides. Am. J. Physiol., in press.
11. L. Frick and R. Wolfenden: Mechanistic implications of the inhibition of peptidases by amino aldehydes and bestatin. Biochim. Biophys. Acta 829, 311-318 (1985).
12. H. Umezawa: Small molecular weight immunomodifiers produced by microorganisms. In "Small Molecular Immunomodifiers of Microbial Origin" (H. Umezawa, ed.) pp. 1-16. Pergamon Press, New York, 1980.
13. N. Kumano and S. Sugawara: Ubenimex (bestatin), an aminopeptidase inhibitor, modulates protein kinase C in K562 cells. J. Biol. Regul. Homeostat. Agents 6, 116-120 (1992).
14. +/dipeptide cotransport system. J. Pharmacol. Exp. Ther. 252, 859-862 (1990).
15. + coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes. J. Pharmacol. Exp. Ther. 260, 482-486 (1992).
16. H. Miyazaki: Pharmacokinetics and metabolism of bestatin in humans and rats by gas chromatography-mass spectrometry. In "Small Molecular Immunomodifiers of Microbial Origin" (H. Umezawa, ed.) pp. 217-229. Pergamon Press, New York, 1980.
17. T. Ueda, K. Tohyama, Y. Wano, H. Tsutani, T. Fukushima, H. Iwasaki, Y. Urasaki, N. Gotoh, S. Kimura, and E. Okumura: Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome. Anticancer Res. 14, 2093-2097 (1994).
18. 3H]ubenimex in IMC carcinoma-bearing mice. Int. J. Immunopharmacol. 12, 755-760 (1990).
19. C. Crone and D. G. Levitt: Capillary permeability to small solutes. In "Handbook of Physiology, Section 2, Volume IV: Microcirculation" (E. M. Renkin and C. C. Michel, eds.), pp. 411-466. American Physiological Society, Bethesda, MD, 1984.
20. P. Kruhøffer: The significance of diffusion and convection for the distribution of solutes in the intestinal space. Acta Physiol. Scand. 11, 37-47 (1946).
21. N. Deane, G. E. Schreiner, and J. S. Robertson: The velocity of distribution of sucrose between plasma and interstitial fluid, with reference to the use of sucrose for the measurement of extracellular fluid in man. J. Clin. Invest. 30, 1463-1468 (1951).
22. E. M. Renkin: Effects of blood flow on diffusion kinetics in isolated perfused hindlegs of cats. Am. J. Physiol. 183, 125-136 (1955).
23. E. M. Renkin and J. P. Gilmore: Glomerular filtration. In "Handbook of Physiology. Section 8: Renal Physiology" (J. Orloff and R. W. Berliner, eds.), 1st ed., pp. 185-248. American Physiological Society, Washington, D.C., 1973. (See also Table 14, p. 229.)
24. A. L. Jones: Anatomy of the normal liver. In "Hepatology" (D. Zakim and T. D. Boyer, eds.), pp. 3-32. W. B. Saunders Co., Philadelphia, 1996.
25. W. E. G. Müller, D. K. Schuster, R. K. Zsahn, A. Maidhof, G. Leyhausen, D. Falke, R. Koren, and H. Umezawa: Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int. J. Immunopharmacol. 4, 393-400 (1982).
26. H. Kohno, S. Kanda, and T. Kanno: Immunoaffinity purification and characterization of leucine aminopeptidase from human liver. J. Biol. Chem. 261, 10744-10748 (1986).
27. A. Taylor: Aminopeptidases: towards a mechanism of action. Trends Biol. Sci. 18, 167-172 (1993).
28. J. L. Gollan (ed.): The molecular basis of hepatic transport. Semin. Liver Disease 16, 107-230 (1996).
29. R. Hori, Y. Tomita, T. Katsura, M. Yasuhara, K. Inui, and M. Takano: Transport of bestatin in rat renal brush-border membrane vesicles. Biochem. Pharmacol. 45, 1763-1768 (1993).
30. H. Saito, T. Terada, M. Okuda, S. Sasaki, and K. Inui: Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim. Biophys. Acta 1280, 173-177 (1996).
31. D. M. Mathews: "Protein Absorption, Development and Present State of the Subject," pp. 235-364. Wiley-Liss, New York, 1991.
32. F. H. Leisbach and V. Ganapathy: Peptide transporters in the intestine and kidney. Annu. Rev. Nutr. 16, 99-119 (1996).
33. L. D. Isenman and J. F. Dice: Selective release of peptides from lysosomes. J. Biol. Chem. 268, 23856-23859 (1993).
34. M. T. Heemels and H. Ploegh: Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64, 463-491 (1995).
35. +/peptide cotransporter mediating absorption of β-lactam antibiotics in the intestine and kidney. J. Pharmacol. Exp. Ther. 275, 1631-1637 (1995).